Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge

Sun, Si; Li, Entao; Zhao, Gan; Tang, Jie; Zuo, Qianfei; Cai, Larry; Xu, Chuanfei; Sui, Cheng; Ou, Yangxue; Liu, Chang; Li, Haibo; Ding, Yuan; Li, Chao; Lu, Dongshui; Zhang, Weijun; Luo, Ping; Cheng, Ping; Gao, Yuwei; Tu, Changchun; Pitard, Bruno; Rosenecker, Joseph; Wang, Bin; Liu, Yan; Zou, Quanming; Guan, Shan

doi:10.1016/j.biomaterials.2022.121907

Cited by 17 publications

(13 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54 Addressing the recent COVID pandemic, researchers have published a cluster of papers ranging from virus detection, generation of ex vivo models, mitigation of viral inflammation, and therapy. [55][56][57][58][59] Several papers also describe innovative vaccine designs that should help fight future pandemics. 56,[60][61][62][63][64] This is only a glimpse of the many interesting papers innovating in biomaterials science and engineering.…”

Section: Biomaterials Research In Advanced Materials (Ekaterina Peret...mentioning

confidence: 99%

“…Addressing the recent COVID pandemic, researchers have published a cluster of papers ranging from virus detection, generation of ex vivo models, mitigation of viral inflammation, and therapy 55–59 . Several papers also describe innovative vaccine designs that should help fight future pandemics 56,60–64 …”

Section: Biomaterials (Kam W Leong Phd Editor‐in‐chief)mentioning

confidence: 99%

See 1 more Smart Citation

The Year 2022 in biomaterials research: A perspective from the editors of six leading journals

Stegemann

Wagner

Göbel

et al. 2023

J Biomedical Materials Res

View full text Add to dashboard Cite

The field of biomaterials science is highly active, with a steadily increasing number of publications and new journals being founded. This article brings together contributions from the editors of six leading journals in the area of biomaterials science and engineering. Each contributor highlights specific advances, topics, and trends that have emerged through the publications in their respective journal in the calendar year 2022. It presents a global perspective on a wide range of material types, functionalities, and applications. The highlighted topics include a diversity of biomaterials; from proteins, polysaccharides, and lipids to ceramics, metals, advanced composites, and a variety of new forms of these materials. Important advances in dynamically functional materials are presented, including a range of fabrication techniques such as bioassembly, 3D bioprinting and microgel formation. Similarly, several applications are highlighted in drug and gene delivery, biological sensing, cell guidance, immunoengineering, electroconductivity, wound healing, infection resistance, tissue engineering, and treatment of cancer. The goal of this paper is to provide the reader with both a broad view of recent biomaterials research, as well as expert commentary on some of the key advances that will shape the future of biomaterials science and engineering.

show abstract

Section: Biomaterials Research In Advanced Materials (Ekaterina Peret...mentioning

confidence: 99%

Section: Biomaterials (Kam W Leong Phd Editor‐in‐chief)mentioning

confidence: 99%

The Year 2022 in biomaterials research: A perspective from the editors of six leading journals

Stegemann

Wagner

Göbel

et al. 2023

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…196 Self-assembled peptidepoloxamine NPs can also generate resident memory T cell responses through pulmonary inoculation, due to their mucuspenetrating properties (Figure 3g,h). 197 Overall, antigen depots generating sustained vaccine delivery efficiently maximize antigen exposure at injection sites, which facilitates the immune cell recruitment and activation required for continuous immunity stimulation. Below, we discuss the role of nanoadjuvants in reinforcing this exciting possibility by influencing subsequent immune responses.…”

Section: Vaccines Contribute To Long-lasting Immunitymentioning

confidence: 99%

“…The nanovaccine with pH effect, referred to as Ad5@oligoCS, and was shown to promote mucosal adhesion and retention, demonstrating that Ad5@oligoCS enables to promote phagocytosis-mediated uptake, even in local and distant mucosal-associated lymphoid tissues, and high levels of mucosal IgA antibodies and T cell immunity (Figure f) . Self-assembled peptide-poloxamine NPs can also generate resident memory T cell responses through pulmonary inoculation, due to their mucus-penetrating properties (Figure g,h) …”

Section: Vaccines Contribute To Long-lasting Immunitymentioning

confidence: 99%

Nanovaccines for Advancing Long-Lasting Immunity against Infectious Diseases

Gao,

Wang,

et al. 2023

ACS Nano

View full text Add to dashboard Cite

“…The nasal compartment contains an abundant viral entry receptor (ACE2) and an activating protease (TMPRSS2), which leads to high susceptibility to viral infection . Thus, mucosal vaccination by the intranasal route could stimulate the sterilizing and localized mucosal immunity . Mucosal immunity could provide a first line of defense against respiratory pathogens, which has the advantage of potentially preventing viral transmission of the respiratory tract in the early phase .…”

Section: Introductionmentioning

confidence: 99%

Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration

Xiao

Wang

Shen

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

SARS-CoV-2 is a respiratory virus that causes significant threats to human health. Mucosal immunity provides a first-line defense to prevent the infection of SARS-CoV-2 in the respiratory tract. Because most SARS-CoV-2 vaccines could not stimulate mucosal immunity in the respiratory tract, appropriate mucosal adjuvants or delivery systems are needed for mucosal vaccine development. Mannan, polyarginine, and 2′,3′-cGAMP are three mucosal adjuvants that could stimulate mucosal immunity. In the present study, the three adjuvants were assembled with a receptor-binding domain (RBD) by electrostatic interaction to generate a nanoparticle vaccine (RBD-MP-cG). RBD-MP-cG elicited mucosal IgA and IgG response in bronchoalveolar lavage and nasal lavage by intranasal administration. It induced a robust RBD-specific antibody response, high levels of protective neutralizing antibody, and ACE2-blocking activity in the mouse sera. It stimulated the splenic secretion of high levels of Th1-, Th2-, and Th17-type cytokines. Thus, RBD-MP-cG elicited strong mucosal immunity and systematic immunity by intranasal administration. RBD-MP-cG was expected to act as a safe, effective, and easily produced mucosal nanoparticle vaccine to combat the infection of SARS-CoV-2.

show abstract

Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge

Cited by 17 publications

References 83 publications

The Year 2022 in biomaterials research: A perspective from the editors of six leading journals

The Year 2022 in biomaterials research: A perspective from the editors of six leading journals

Nanovaccines for Advancing Long-Lasting Immunity against Infectious Diseases

Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration

Contact Info

Product

Resources

About